Well it is not possible to know what the FDA looked at and how they arrived at their position ... I can only imagine they looked at each DP and categorised them by the amount of TNF1 ... there may have only been a small variance between the subgroups, but they may have tried to see if a higher concentrated TNF1 DP resulted in a better clinical outcome.
I think the only way to know is to possibly give a large cohort a dose from a DP with significantly lower concentration of TFN1.. and the other cohort gets a high concentration DP.
Mesoblast were able to demonstrate it in vitro, but the trial wasn’t set up to demonstrate this in vivo
- Forums
- ASX - By Stock
- MSB
- FDA ODAC Meeting Material discussion analysis
FDA ODAC Meeting Material discussion analysis, page-375
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.01 |
Change
0.030(3.06%) |
Mkt cap ! $1.153B |
Open | High | Low | Value | Volume |
$1.01 | $1.04 | 99.0¢ | $5.111M | 5.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 211966 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 136540 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 48333 | 1.005 |
3 | 49000 | 1.000 |
3 | 80800 | 0.995 |
5 | 129515 | 0.990 |
1 | 3300 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 136540 | 9 |
1.025 | 63000 | 3 |
1.030 | 28077 | 3 |
1.040 | 27850 | 2 |
1.045 | 103431 | 6 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |